Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity
Joint Authors
Chae, Hyojin
Koh, Yoon-Seok
Hwang, Byung-Hee
Kang, Min-Kyu
Kim, Yonggoo
Park, Hae-il
Chang, Kiyuk
Kim, Myungshin
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-03-28
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Clopidogrel is a prodrug which is converted into active metabolite by cytochrome P450 isoenzyme, CYP2C19.
Numerous polymorphisms of CYP2C19 are reported, and a strong link exists between loss-of-function (LOF) or gain-of-function polymorphisms, clopidogrel metabolism, and clinical outcome.
Hence, a fully automated point-of-care CYP2C19 genotyping assay is more likely to bring personalized antiplatelet therapy into real practice.
We assessed the feasibility of the Verigene 2C19/CBS Nucleic Acid Test, a fully automated microarray-based assay, compared to bidirectional sequencing, and performed VerifyNow P2Y12 assay to evaluate the effect of CYP2C19 polymorphisms on on-treatment platelet reactivity in 57 Korean patients treated with clopidogrel after percutaneous coronary intervention.
The Verigene 2C19/CBS assay identified *2, *3, and *17 polymorphisms with 100% concordance to bidirectional sequencing in 180 minutes with little hands-on time.
Patients were classified into 4 groups: extensive (*1/*1; n=12, 21.1%), intermediate (*1/*2, *1/*3; n=33, 57.9%), poor (*2/*2, *2/*3, and *3/*3; n=11, 19.3%), and ultrarapid metabolizers (*1/*17; n=1, 1.8%).
The prevalence of the CYP2C19 *2, *3, and *17 alleles was 36.0%, 12.3%, and 0.9%.
Platelet reactivity showed gene dose response according to the number of CYP2C19 LOF allele.
In conclusion, the Verigene 2C19/CBS assay gave accurate CYP2C19 genotype results which were in well match with the differing on-treatment platelet reactivity.
American Psychological Association (APA)
Chae, Hyojin& Kim, Myungshin& Koh, Yoon-Seok& Hwang, Byung-Hee& Kang, Min-Kyu& Kim, Yonggoo…[et al.]. 2013. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International،Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
Modern Language Association (MLA)
Chae, Hyojin…[et al.]. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International No. 2013 (2013), pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
American Medical Association (AMA)
Chae, Hyojin& Kim, Myungshin& Koh, Yoon-Seok& Hwang, Byung-Hee& Kang, Min-Kyu& Kim, Yonggoo…[et al.]. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1030134